Institute of Pharmaceutical Sciences

OVERVIEW
The Institute of Pharmaceutical Sciences was created on October 29, 1998 during the 1125th UP Board of Regents (BOR) meeting. The IPS envisions itself to become a recognized and relevant institution in the pharmaceutical sciences by providing the facilities, pertinent expertise and comprehensive services, including human resource development to help ensure the provision of safe, effective and quality drugs for the nation.
VISION
The Institute of Pharmaceutical Sciences shall continually strive to become a recognized and relevant institution in the pharmaceutical sciences by providing facilities, pertinent expertise and comprehensive services, including human resource development, to help ensure the provision of safe, effective and quality drugs and pharmaceutical preparations for the nation with due regard to public health impact and safety.
MISSION
To address the research and technical needs of various sectors and stakeholders in the study, provision and utilization of safe, cost-effective and efficacious indigenous and synthetic pharmaceutical preparations.
RESEARCH AGENDA
In order to meet its mission, the IPS shall conduct researches on the following three major areas:
- Drug Development - This area aims to come up with cheaper but quality drug alternatives and cost effective pharmaceutical preparations including cosmetic products. Research studies covered in this area include: drug discovery and development, cosmetics product development and efficacy testing, product pre formulation and/or formulation, stability studies, pre-clinical and clinical testing of pharmaceutical formulations.
- Pharmacy Practice - Researches in this field are conducted to improve the practice of pharmacy in the country. Scope of this research area includes: rational drug use, clinical pharmacy services and practice, pharmacy education, public health pharmacy, patient safety, outcomes research and pharmaco-economics studies, pharmaco-epidemiology and policy review and formulation.
- Bioavailability/Bioequivalence Testing - Timely and relevant researches to validate both in vitro and in vivo studies on dissolution-bioavailability will be performed in this area. Local as well as multinational drug companies are expected to benefit from this endeavor. Research studies include in vitro dissolution testing, in vitro-in vivo correlation studies and BioA/BioE studies.
SERVICES
The Institute of Pharmaceutical Sciences offers the following services to students and non-students:
TYPE OF ANALYSIS |
REQUIREMENTS |
LEAD TIME |
RATE, P |
NATURAL PRODUCTS |
|||
Extraction (Maceration) |
Pulverized sample (at least 250 g), procedure (type of solvent to be used, weight-solvent ratio, etc.) |
10 working days (For special cases, i.e. longer soaking time, lead time will depend on the analyst) |
500/250 g sample |
Phytochemical screening (qualitative) |
Plant extract (at least 2 g for crude extract and 60 mL for extracts in their mother solvent)
|
10 working days |
700 |
Total flavonoids |
Plant extract (at least 1 g of crude extract or depending on the concentration of the sample)
|
10 working days |
2,000 |
Total phenolics |
Plant extract (at least 1 g of crude extract or depending on the concentration of the sample)
|
10 working days |
1,500 |
Total tannins |
Plant extract (at least 1 g of crude extract or depending on the concentration of the sample)
|
10 working days |
3,500 |
Isolation of tannins |
Plant extract (at least 1 g of crude extract or depending on the concentration of the sample)
|
10 working days |
1,200 |
Thin layer chromatography |
Plant extract (at least 1 g of crude extract), procedure (solvent system, visualization technique, etc.)
|
10 working days |
500 |
DPPH radical scavenging assay |
Plant extracts (at least 1 g), concentrations to be used |
10 working days |
1500/5 conc. |
FRAP assay |
Plant extracts (at least 1 g), concentrations to be used
|
10 working days |
1300/5 conc. |
PHARMACEUTICAL PRODUCTS |
|||
Potency assay |
Samples (tablet/capsules: 40 pcs., ampoules/vials/suspensions: 4 pcs.), procedure, reference/working standard, certificate of analysis (standard and finished product) |
1-1.5 months |
4,200/sample |
RESEARCHES
These are the research projects the Institute have accomplished and are currently doing (from 2014 to present):
|
Title |
Year |
Funding Agency |
1 |
Screening for Antioxidant and Antimicrobial Activities of Some Plants for Potential Use as Preservatives
|
2013-2014 |
NIH |
2 |
Alternative and Sustainable Resources of Natural Preservatives
|
2014-2015 |
NRCP |
3 |
Extraction and Purification of Pectin from Fruit Peel Waste of Selected Philippine Fruits
|
2014-2015 |
NRCP |
4 |
Anti-inflammatory and Wound Healing Property of Coconut Germ Oil
|
2014-2015 |
NIH |
5 |
In-Vitro Equivalence Testing of Selected Generic Essential Medicines Eligible for BCS-Based Biowaiver
|
2014-2016 |
PCHRD-DOST |
6 |
Antioxidant and Antimicrobial Property of Caesalpinia pulcherrima (L.) Swartz
|
2015-2016 |
IPS |
7 |
Extraction, Purification, and Evaluation of Selected Fruit Waste-Derived Starch as Pharmaceutical Excipients
|
2016-2017 |
PITAHC |
8 |
Extraction and Bioassay Evaluation of Selected Philippine Plants for Diabetes, Hyperlipidemia, and Hypertension
|
2016-2018 |
NRCP |
9 |
Evaluation of Safety and Efficacy of Makabuhay Thin Ointment against Head Lice
|
2016-2017 |
PITAHC |
10 |
Extraction and Physicochemical Characterization of Chitin from Molluscan Shell Wastes
|
2016-2017 |
IPS |
11 |
Development and Evaluation of Anti-Inflammatory and Wound-Healing Gel Preparation containing Cocos nucifera Germ Oil
|
2016-2017 |
NIH |
12 |
Antimicrobial Activity of Calcium Hydroxide, Chlorhexidine, C. pulcherrima and Their Combination in E. faecalis and C. albicans
|
2016-2017 |
NIH |
13 |
Evaluation of safety and efficacy of Siling labuyo liniment for the management of Osteoarthritis
|
2016-2017 |
PITAHC |
14 |
An Evaluation of the Safety and Efficacy of Community-produced Senna alata (Akapulko) 50% Thin Ointment Compared to Clottimazole 1% Cream in the Treatment of Pityriasis Versicolor: An assessor-blinded, randomized controlled trial |
2016-2017 |
PITAHC |
STAFF
Erna C. Arollado, RPh., MSc., PhD.
Director
Ana Rose V. Palmes
Administrative Officer
Richelle Ann M. Manalo, RCh.
University Researcher
Gerwin Louis T. Dela Torre, RPh.
University Research Associate I
Joriza Mae M. Pellazar, RPh.
Research Associate
Mae Pauline F. Siocson
Research Assistant
Shaina Mara M. Salvador
Research Assistant
Patrick Jacob L. Liwag, RCh.
Research Assistant
Angelica Louise D. De Guzman, RCh.
Research Assistant
Clarisse Julian A. Pangilinan, RCh.
Research Assistant
Romeo-Luis F. Ramirez
Research Assistant
CONTACT INFORMATION
Tel. No: (02) 577-2001/0917 838 6327
E-Mail Address: ips_nih@yahoo.com
Address: Institute of Pharmaceutical Sciences
Room 212, National Institutes of Health
University of the Philippines Manila, P. Gil St., Ermita, Manila